

Table 3. Detected NNRTI-resistance mutations, combinations and their impact on NNRTI drugs susceptibility in 128 cases, Libya, 2014–2017

Mutations	EFV	NVP	ETR	RPV	DOR
A98G	15	30	10	15	15
A98G + Y181C	5	5	5	5	5
A98G + F227L	15	15	15	15	15
L100I	60	60	30	60	15
L100I + K103HNSV	0	0	0	0	15
L100I + K103HNSV + P225H	0	0	0	0	-10
K101EHP	60	60	60	60	15
K101EHP + G190AES	0	0	5	0	5
K103HNSV + Y181C	0	0	0	0	5
K103HNSV + P225H	0	0	0	0	10
V106M	60	60	0	0	30
V108I	10	15	0	0	10
V108I + Y181C	0	0	0	0	5
E138AGKQ	10	10	10	45	5
Y181C	30	60	30	45	10
Y181C + G190AES	0	0	10	10	10
Y181C + H221Y	0	0	0	10	10
Y188FHL	60	60	10	60	60
G190AES	60	60	45	60	60
H221Y	10	15	10	15	10
P225H	45	45	0	0	20
F227L	15	30	0	0	60
M230IL	45	60	30	60	60
Y318F	10	30	0	0	60
K101EHP + Y181C	5	5	5	0	0
K103HNSV	60	60	0	0	0
V179ET	10	10	10	10	0
K238NT	30	30	0	0	0
K101EHP + Y188FHL	0	0	5	0	0
V179ET + Y181C	0	0	10	10	0
K101EHP + M184IV	0	0	0	15	0
E138AGKQ + M184IV	0	0	0	15	0

Note: These numbers represent the effect or weighting of each mutation or combination of mutations on individual drug susceptibility. Positive numbers mean reduced susceptibility whereas negative numbers mean increased sensitivity. The larger the number, the more the effect on drug susceptibility when a particular mutation/combination is present.

NNRTIs: Non-nucleoside reverse transcriptase inhibitors; EFV: Efavirenz; NVP: Nevirapine; ETR: Etravirine; RPV: Rilpivirine; DOR: Doravirine.